- Record: found
- Abstract: found
- Article: not found
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni
1 ,
Wolfgang Eiermann ,
Vladimir Semiglazov ,
Alexey Manikhas ,
Ana Lluch ,
Sergey Tjulandin ,
Milvia Zambetti ,
Federico Vazquez ,
Mikhail Byakhow ,
Mikhail Lichinitser ,
Miguel Angel Climent ,
Eva Ciruelos ,
Belén Ojeda ,
Mauro Mansutti ,
Alla Bozhok ,
Roberta Baronio ,
Andrea Feyereislova ,
Claire Barton ,
Pinuccia Valagussa ,
Jose Baselga
Jan 30 2010
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The monoclonal antibody trastuzumab has survival benefit when given with chemotherapy to patients with early, operable, and metastatic breast cancer that has HER2 (also known as ERBB2) overexpression or amplification. We aimed to assess event-free survival in patients with HER2-positive locally advanced or inflammatory breast cancer receiving neoadjuvant chemotherapy with or without 1 year of trastuzumab.